



首页

最新一期

期刊动态

过刊浏览

医学视频

在线投稿

期刊检索

期刊订阅

合作科室

注册
登录

您的位置: [首页](#)>> 文章摘要

炎症性肠病内科治疗进展

周星璐, 潘文胜

310009 杭州, 浙江大学医学院附属第二医院消化内科

潘文胜, Email: wspan223@yahoo.com

卫生行业科研专项项目资助(200802112); 浙江省自然科学基金(Y12H160121, Y208001); 浙江省科技厅重大(2009C03012-5); 浙江省医药卫生科学研究基金(2008A094, 2011KYA167, 2012KYB232)

关键词: 肠病

[评论](#) [收藏](#) [全](#)

文献标引: 周星璐, 潘文胜. 炎症性肠病内科治疗进展[J/CD]. 中华临床医师杂志: 电子版, 2013, 7(16): 7362-73

参考文献:

- [1] 中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2012年, 志, 2012, 32: 796-813.
- [2] Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: a systematic review and meta-analysis. *Am J Gastroenterol*, 2011, 106: 601-616.
- [3] 郑家驹. 顺序性治疗途径在炎症性肠病中的应用. *中华消化杂志*, 2012, 32: 872-875.
- [4] Lim WC, Hanauer S. Aminosaliclates for induction of remission or response in Crohn's disease. *Cochrane Database Syst Rev*, 2010: CD008870.
- [5] Ford AC, Khan KJ, Achkar JP, et al. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. *Am J Gastroenterol*, 2012, 107: 167-176; author reply 177.
- [6] Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Guidelines for the diagnosis and management of IBD in 2010. *Inflamm Bowel Dis*, 2010, 16: 1300-1319.
- [7] Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. *Gut*, 2011, 60: 571-607.
- [8] Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in Crohn's disease. *Cochrane Database Syst Rev*, 2012: CD000544.
- [9] BARON JH, CONNELL AM, KANAGHINIS TG, et al. Out-patient treatment of ulcerative colitis with oral 5-aminosalicylic acid. *Gut*, 2001, 48: 100-104.

期刊导读

7卷20期 2013年10月 [最新]



期刊存档

期刊存档

[查看目录](#)

期刊订阅



在线订阅



邮件订阅



RSS

作者中心



资质及晋升信息



作者查稿



写作技巧



投稿方式



作者指南

编委会

期刊服务



建议我们



会员服务



广告合作



继续教育

[10] Ooi CJ, Fock KM, Makharia GK, et al. The Asia-Pacific consensus on ulcerative colitis. *Gastroenterol Hepatol*, 2010, 25: 453-468.

[11] Cheifetz AS, Stern J, Garud S, et al. Cyclosporine is safe and effective in severe ulcerative colitis. *J Clin Gastroenterol*, 2011, 45: 107-112.

[12] Prefontaine E, Sutherland LR, Macdonald JK, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. *Cochrane Database Syst Rev*, 2009: CD000000.

[13] Timmer A, McDonald JW, Tsoulis DJ, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. *Cochrane Database Syst Rev*, 2012: CD000478.

[14] Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Current management. *J Crohns Colitis*, 2010, 4: 1-26.

[15] Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in Crohn's disease. *Cochrane Database Syst Rev*, 2003: CD003459.

[16] Ng SC, Chan FK, Sung JJ. Review article: the role of non-biological drugs in the management of inflammatory bowel disease. *Aliment Pharmacol Ther*, 2011, 33: 417-427.

[17] Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. *Clin Gastroenterol Hepatol*, 2008, 6: 644-653.

[18] Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. *Dig Liver Dis*, 2007, 39: 397-408.

[19] Panaccione R, Rutgeerts P, Sandborn WJ, et al. Review article: treatment of Crohn's disease to achieve remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. *Aliment Pharmacol Ther*, 2008, 28: 674-688.

[20] Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. *Gut*, 1994, 35: 360-362.

[21] Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. *Gastroenterology*, 2010, 138: 463-468; quiz 469.

[22] Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic remission in Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. *Gastroenterology*, 1990, 98: 811-818.

[23] Ordas I, Feagan BG, Sandborn WJ. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change. *Gut*, 2011, 60: 1754-1763.

[24] Cohen BL, Torres J, Colombel JF. Immunosuppression in inflammatory bowel disease: is it used too much. *Curr Opin Gastroenterol*, 2012, 28: 341-348.

[25] Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior in Crohn's disease. *Inflamm Bowel Dis*, 2002, 8: 244-250.

- [26] Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine in children with newly diagnosed Crohn's disease. *Gastroenterology*, 2000, 119: 895-901.
- [27] D'Haens G, Baert F, van AG, et al. Early combined immunosuppression or conventional therapy in patients with newly diagnosed Crohn's disease: an open randomised trial. *Lancet*, 2001, 357: 851-859.
- [28] Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. *N Engl J Med*, 2010, 362: 1383-1395.
- [29] Cohen BL, Torres J, Colombel JF. Immunosuppression in inflammatory bowel disease: too much. *Curr Opin Gastroenterol*, 2012, 28: 341-348.
- [30] Tamboli CP, Doman DB, Patel A. Current and future role of biomarkers in Crohn's disease: assessment and treatment. *Clin Exp Gastroenterol*, 2011, 4: 127-140.
- [31] Hammer HF. Gut microbiota and inflammatory bowel disease. *Dig Dis*, 2011, 29: 10-17.
- [32] Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel disease: antibiotics, probiotics, and prebiotics. *Gastroenterology*, 2004, 126: 1620-1633.
- [33] Shamir R, Phillip M, Levine A. Growth retardation in pediatric Crohn's disease: causes and interventions. *Inflamm Bowel Dis*, 2007, 13: 620-628.
- [34] Lochs H, Dejong C, Hammarqvist F, et al. ESPEN Guidelines on Enteral Nutrition in Inflammatory Bowel Disease. *Gastroenterology*. *Clin Nutr*, 2006, 25: 260-274.
- [35] Ioannidis O, Varnalidis I, Paraskevas G, et al. Nutritional modulation of the gut microbiota and bowel response. *Digestion*, 2011, 84: 89-101.
- [36] Orenstein SR. Polymeric diet alone versus corticosteroids in the treatment of Crohn's disease. *Curr Gastroenterol Rep*, 2007, 9: 205-207.
- [37] Verma S, Kirkwood B, Brown S, et al. Oral nutritional supplementation is effective for the maintenance of remission in Crohn's disease. *Dig Liver Dis*, 2000, 32: 769-774.
- [38] 朱水津. 炎症性肠病的营养治疗. *医学综述*, 2012, 18: 3624-3626.
- [39] Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. *Nature*, 2007, 448: 427-434.
- [40] 冉志华. 益生菌制剂在炎症性肠病中的应用. *中国实用内科杂志*, 2007, 27: 1414-1416.
- [41] Meijer BJ, Dieleman LA. Probiotics in the treatment of human inflammatory bowel disease: update 2011. *J Clin Gastroenterol*, 2011, 45 Suppl: S139-144.
- [42] Jonkers D, Penders J, Masclee A, et al. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. *Drugs*, 2012, 72: 103-114.
- [43] Hering NA, Fromm M, Schulzke JD. Determinants of colonic barrier function in Crohn's disease and potential therapeutics. *J Physiol*, 2012, 590: 1035-1044.

肠道炎症性疾病的治疗

李玥, 钱家鸣. . 中华临床医师杂志: 电子版
2013;7(16):7349-7350.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

早期胃癌的治疗现状

晏维, 田德安. . 中华临床医师杂志: 电子版
2013;7(16):7351-7353.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

炎症性肠病的现代内科治疗

钟英强, 叶小研. . 中华临床医师杂志: 电子版
2013;7(16):7354-7357.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

肠道疾病的内镜下微创治疗进展

徐雷鸣. . 中华临床医师杂志: 电子版
2013;7(16):7358-7361.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

炎症性肠病内科治疗进展

周星璐, 潘文胜. . 中华临床医师杂志: 电子版
2013;7(16):7362-7365.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

低位直肠癌保肛手术新进展

赵任, 蒋奕玫. . 中华临床医师杂志: 电子版
2013;7(16):7366-7368.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

功能性胃肠病之肠易激综合征的个体化治疗

李兴华. . 中华临床医师杂志: 电子版
2013;7(16):7369-7370.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

浅谈大肠癌的病因预防

毛华, 黄丽韞. . 中华临床医师杂志: 电子版
2013;7(16):7371-7373.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

结直肠息肉患者的化学治疗与预防研究进展

朱元民. . 中华临床医师杂志: 电子版
2013;7(16):7374-7377.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

肠道菌群失调、肠上皮功能障碍与肥胖症的研究

凌贤龙, 陈代兴. . 中华临床医师杂志: 电子版
2013;7(16):7378-7380.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

